Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Why can't I see the RNS? Had to go to the website to find this (which is long on froth and short on details, like how much did it cost?).
https://www.gamaaviation.com/news/business-aviation/gama-aviation-acquires-jet-east/
But I'm glad to see they're active.
SP now highest since 2017.
Looks good to me....
"The second half of the year has seen strong momentum built with recurring revenue bookings 80% higher than in the first half, achieved from both existing and new customers. Momentum has been driven by the significant growth in online retail, the addition of innovative Artificial Intelligence (AI) Search capabilities which were acquired from Aleph Search in October 2020, and a continued focus on execution. Consequently, revenue and EBITDA for the full year are expected to show growth in line with market expectations.
The Group signed 38 multi-year contract renewals in the year, compared with 21 renewals in 2019. The second half of the year has seen strong momentum built with recurring revenue bookings 80% higher than in the first half, achieved from both existing and new customers. Momentum has been driven by the significant growth in online retail, the addition of innovative Artificial Intelligence (AI) Search capabilities which were acquired from Aleph Search in October 2020, and a continued focus on execution. Consequently, revenue and EBITDA for the full year are expected to show growth in line with market expectations.
The Group signed 38 multi-year contract renewals in the year, compared with 21 renewals in 2019. "
@philpot I'm not young either, but the ethical focus was a prequisite for me buying here. Was very pleased to see a palm oil producer that looked to be a good investment and also I could invest in with a good conscience. When there's choice why not pick a good one? Plus, to be totally mercenary about it too (!), ESG companies usually do better in the long run anyway.
Continued...
3. Testing going on as strongly as ever. Antigen tests seem to be the most used at the moment [my perception], and ours picks up the new variant. Plus:
"The Group's COVID-19 antigen test has 4+1 gene discovery capability, including the S protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. The Group is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and other geographies."
4. Whole new area opening up, in which we not only have the lead, but also a major customer: "the delivery of the first of its new instrument that recovers high-quality protein and oils from insects to a world renowned company focused on commercialising industrial scale insect-based technologies to produce feedstock."
This could be bigger than any of us realise. I suspect following the pandemic the production of food may change radically the world over in the next 10 years. Oil for fish production is a particular problem.
Agreed. Everything seemed to have gone a bit quiet since the stonking interims in August [EPS +157.1%] - and the SP down nearly 25%!
It hasn't gone quiet - though Marom may have a bit, no more "feeding the rabbits the very best carrots"!
1. Great results, as above.
2. Really really interesting update re Ador in December, into which some of this money from NGSoft may be going:
"The Boards of Ador and of BATM believe that there is a substantial market opportunity for an RCA-based sample-to-answer solution that is able to be used at the point of care as well as in laboratories for the diagnosis of infectious disease. The speed and accuracy of identifying an infection can be vital in providing the correct treatment and in containing potential disease outbreaks. As a result, Ador has taken the strategic decision to focus its resources on developing this ground-breaking technology while continuing to advance its PCR-based NATlab system.
Investment of $10m into Ador
To expedite the development of the new RCA-based system, the Group and all its partners in Ador have invested an additional amount of $10m, of which BATM has contributed $3m, pursuant to an amendment to the investment agreement announced on 28 January 2019. Following this additional investment, the Group's shareholding in Ador is 36.7%."
This new equipment looks amazing:
"Ador has developed a new innovative technology based on the polymerase chain reaction ("PCR") process as well as an isothermal method called rolling circle amplification ("RCA") to enable NATlab to increase the speed of providing sample-to-answer diagnostics to under 30 minutes.
RCA-based molecular diagnosis offers significant advantages compared with the PCR process. Due to the different methods for replicating the genetic material in a sample, RCA is less prone to errors and the reaction with the test material occurs in c. 15-20 minutes compared with c. 60-90 minutes for PCR. As a result, the NATlab system will now be able to provide test results in a significantly shorter amount of time and with greater accuracy than first envisaged.
The NATlab can analyse several pathogens (currently up to 400) at the same time thus enabling it to detect all the possible pathogens associated with diseases such as meningitis, sepsis and respiratory diseases. By accurately detecting the right strain of a disease, the correct treatment can be started immediately - something that is not possible with the PCR methods that exist today. In addition, the development timeframe for the NATlab to be able to test for new pathogens is up to 10 times shorter than for existing solutions, which would be a significant advantage during epidemics and pandemics of a novel disease."
Worth reading the whole RNS. In-hospital trials H1 2021.
With Biden now having taken the Senate as well I expect his aggressive green infrastructure plans will benefit Somero. Almost everything uses concrete, and a great deal of infrastructure needs renewal.
And it won't do any harm to show main street America that Democrats spending money benefits the the gun-toting hard man in the street.
Non-exec Chairman buying £244,000 worth of shares. That's some recommendation. :))
So much opportunity elsewhere that I've taken a topslice today, after such a great rise in just a couple of months. 70%. But I really believe in this, and will top up again if we have a pullback now, funds permitting.
The rest is now for the long term. It's probably just beginning.
PS. And it's up over 17% today, so you're right about the following!
Just to say about Griffiths, if you're following him: today there was an RNS from Bigblu Broadband (BBB), he's just come in there straight to 5.87% of a £54m mcap company. Encouraging for me, since I bought in there end December :)
On top of our already good list of institutional investors it's great to see Richard Griffiths coming in also, straight up to 5.87%.
Thanks for all your information Rivaldo. I bought this last January after you brought it to my attention and Mark Watson-Mitchell's recommendation. After today's 5.5% I'm up nearly 80%, so thank you! I think his expectation was a 50% rise from 36p, and more recently 70p. Nearly there: how do you see it now?
PS I note Slater and Chelverton are both finding the way in rather than the exit.
Lots of government money backing this. Institutions love it, and they're the ones with great records in smaller companies. I'm in.
Emotionally I want out of this. I sold part last week. But I'm looking at the RNS's, and, bearing in mind I am NO EXPERT, I can't see why the sp has done SO badly. They're still winning contracts, revenue is on a long term rise, they've just moved into profit and are cash positive. The problem from my pov is that they don't seem to have been able to make anything out of the present awful situation which looks like it was made for them. Why not? We don't know.
I'm regretting selling last week, especially as when boards are this negative it is sometimes a great sign!
Last sentence: do you mean you recommend the Sapele over Accoya?
This is from the link below [DigiTimes]:
"Apple's adopting LiDAR based on dToF (direct time of flight) for iPhone 12 Pro, iPhone 12 Pro Max and iPad (2020) is expected to prompt Android smartphone vendors to follow suit, likely to replace indirect ToF (iToF) to become the mainstream 3D depth-sensing technology in 2021.
While major Android phone vendors have integrated less expensive iToF technology with rear cameras, applications have been limited without significantly enhancing user experience. Since dToF can offer significant AR effects, phone vendors are expected to adopt it in place of iToF for their flagship smartphones beginning 2021, Digitimes Research believes.
dToF features low power consumption, resistance to ambient ligh interference, capability to cope with complicated scenarios and accurate ranging, but its technological barriers and production costs are higher.
iToF has higher resolution for 3D depth sensing and is supported by a mature supply chain for lower production cost but consumes more power."
I wonder if this is relevant? From my AMS news on Tuesday, 8th December:
"BUZZ-AMS: Plunges after report on possible Android sensor type change
** Shares in Austria-based sensor specialist AMS AMS.S
plummet 14% and are on track for their worst day in more than
five months
** A trader points to tech website DigiTimes' post http://www.digitimes.com:8080/news/a20201204PD212.html?chid=2,
which says Android phone makers may replace indirect time of
flight sensors (iToF) with direct of flight (dToF) technology
used by Apple AAPL.O , saying it could hurt AMS which supplies
iToF products to Samsung
** However, AMS also makes lasers that are a core part of
Apple's face recognition hardware and has a good chance to
continue supplying them even if the technology changes for the
entire application, an Erste Group analyst says"